Influenza epidemiology in patients admitted to sentinel Australian hospitals in 2017: the Influenza Complications Alert Network (FluCAN).
Adolescent
Adult
Aged
Aged, 80 and over
Australia
/ epidemiology
Case-Control Studies
Comorbidity
Female
Hospitalization
Hospitals
Humans
Influenza B virus
/ classification
Influenza Vaccines
/ immunology
Influenza, Human
/ epidemiology
Male
Middle Aged
Native Hawaiian or Other Pacific Islander
Pregnancy
Sentinel Surveillance
Vaccination
Young Adult
Influenza
influenza vaccines
public health surveillance
vaccination coverage
vaccine effectiveness
Journal
Communicable diseases intelligence (2018)
ISSN: 2209-6051
Titre abrégé: Commun Dis Intell (2018)
Pays: Australia
ID NLM: 101735394
Informations de publication
Date de publication:
16 09 2019
16 09 2019
Historique:
entrez:
17
9
2019
pubmed:
17
9
2019
medline:
11
10
2019
Statut:
epublish
Résumé
The Influenza Complications Alert Network (FluCAN) is a sentinel-hospital-based surveillance program that operates at sites in all jurisdictions in Australia. This report summarises the epidemiology of hospitalisations with laboratory-confirmed influenza during the 2017 influenza season. In this observational surveillance system, cases were defined as patients admitted to any of the 17 sentinel hospitals with influenza confirmed by nucleic acid detection. Data are also collected on a frequency-matched control group of influenza-negative patients admitted with acute respiratory infection. During the period 3 April to 31 October 2017 (the 2017 influenza season), 4,359 patients were admitted with confirmed influenza to one of 17 FluCAN sentinel hospitals. Of these, 52% were elderly (≥65 years), 14% were children (<16 years), 6.5% were Aboriginal and Torres Strait Islander peoples, 1.6% were pregnant and 78% had chronic comorbidities. A significant proportion were due to influenza B (31%). Estimated vaccine coverage was 72% in the elderly (≥65 years), 50% in non-elderly adults with medical comorbidities and 24% in children (<16 years) with medical comorbidities. The estimated vaccine effectiveness (VE) in the target population was 23% (95% CI: 7%, 36%). There were a large number of hospital admissions detected with confirmed influenza in this national observational surveillance system in 2017, with case numbers more than twice that reported in 2016.
Identifiants
pubmed: 31522661
doi: 10.33321/cdi.2019.43.39
doi:
Substances chimiques
Influenza Vaccines
0
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Commonwealth of Australia CC BY-NC-ND.